| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 50mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
BMS-962212 targets Factor XIa (FXIa), a serine protease that is critical for the amplification of the coagulation cascade. FXIa is responsible for the conversion of Factor XI to Factor XIa, which in turn activates Factor IX, leading to downstream thrombin generation and clot formation. BMS-962212 is a direct, reversible, and highly selective inhibitor of FXIa. By binding to FXIa and inhibiting its proteolytic activity, the compound reduces the amplification of the coagulation cascade, thereby decreasing thrombin production and the formation of fibrin clots. This mechanism of action is distinct from that of other anticoagulants, offering a potentially safer approach to thrombosis prevention.
|
|---|---|
| ln Vitro |
In vitro, BMS-962212 has been shown to be a potent and selective inhibitor of FXIa. Its activity is typically assessed using enzyme assays that measure the inhibition of FXIa's proteolytic function. The compound's selectivity is demonstrated by its lack of significant activity against other coagulation factors. In functional assays, BMS-962212 increases activated partial thromboplastin time (aPTT) in a concentration-dependent manner, reflecting its anticoagulant effect on the intrinsic pathway. These in vitro studies confirm the compound's mechanism of action and its potential as an anticoagulant agent.
|
| ln Vivo |
In vivo, BMS-962212 has been shown to be well-tolerated with a fast onset of pharmacodynamic (PD) responses and rapid elimination. In preclinical models and early clinical studies, it has demonstrated efficacy in preventing venous thromboembolism and other thrombotic disorders. The compound's rapid PD response and clearance suggest that it could offer excellent control over anticoagulation, which is a desirable feature for a therapeutic agent. BMS-962212 is being investigated as a next-generation anticoagulant with a potentially lower bleeding risk compared to traditional therapies.
|
| Enzyme Assay |
In vitro enzyme assays for BMS-962212 measure its ability to inhibit the enzymatic activity of Factor XIa. Recombinant human FXIa is incubated with a fluorogenic or chromogenic peptide substrate that mimics its natural cleavage site. The compound is added at varying concentrations, and the rate of substrate cleavage is monitored. The IC50 is determined from the dose-response curve. Selectivity is assessed by testing the compound against a panel of other serine proteases, including other coagulation factors. These assays confirm the compound's potent and selective inhibition of FXIa.
|
| Cell Assay |
In vitro cell-based assays for BMS-962212 are not typically performed, as its mechanism of action is through enzyme inhibition in the blood. However, its effects on coagulation can be studied using plasma-based assays. Human plasma is treated with the compound, and coagulation parameters such as activated partial thromboplastin time (aPTT) are measured. An increase in aPTT indicates an anticoagulant effect. These assays demonstrate the compound's functional activity in a biologically relevant matrix and confirm its ability to modulate the coagulation cascade.
|
| Animal Protocol |
In vivo animal experiments for BMS-962212 have been conducted in models of thrombosis. In a typical study, animals are administered the compound intravenously or orally, and thrombus formation is induced. The compound's ability to reduce thrombus weight or prevent occlusion is measured. Pharmacodynamic parameters, such as the prolongation of aPTT, are also monitored. These studies provide evidence for the compound's efficacy in preventing thrombosis and its rapid onset of action and elimination. Pharmacokinetic parameters are also assessed in these models.
|
| ADME/Pharmacokinetics |
BMS-962212 has a molecular weight of 659.07 g/mol and a molecular formula of C32H28ClFN8O5. It is a solid powder with a purity of ≥98%. For storage, it is recommended to keep the compound at -20°C in a dry, dark environment. In solution, it can be stored at 0-4°C for up to one month. The compound is typically shipped at ambient temperature. Detailed pharmacokinetic parameters, such as half-life and bioavailability, are available from preclinical and early clinical studies. It is characterized by rapid elimination.
|
| Toxicity/Toxicokinetics |
Detailed toxicity data for BMS-962212 is not provided in standard product descriptions. In preclinical studies, the compound has been reported to be well-tolerated. As a Factor XIa inhibitor, it is being developed to offer a safer anticoagulation profile with a lower bleeding risk compared to traditional anticoagulants. However, as with all anticoagulants, there is a potential for bleeding, and its safety profile is being evaluated in ongoing studies. As with all research chemicals, standard laboratory safety precautions should be followed when handling BMS-962212. Its use is limited to research applications.
|
| References | |
| Additional Infomation |
BMS-962212 is a research compound and is not approved for clinical use. It is a direct, reversible, and selective inhibitor of Factor XIa (FXIa), a key enzyme in the intrinsic coagulation pathway. It is being investigated as a potential treatment for preventing venous thromboembolism and other thrombotic disorders, with the goal of providing effective anticoagulation with a lower risk of bleeding compared to existing therapies. The compound's mechanism of action, rapid onset, and rapid elimination make it a valuable tool for studying the role of FXIa in thrombosis and for developing next-generation anticoagulant drugs.
|
| Molecular Formula |
C32H28CLFN8O5
|
|---|---|
| Molecular Weight |
659.066728591919
|
| Exact Mass |
658.185
|
| CAS # |
1430114-34-3
|
| Related CAS # |
1430115-97-1 (HCl);1430114-34-3;
|
| PubChem CID |
71548883
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
0.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
47
|
| Complexity |
1210
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
ClC1=CC=C(C(=C1F)/C=C/C(N1CCC2C(=CC=CC=2[C@H]1C(NC1C=CC(C(=O)O)=CC=1)=O)N1C(CN(C)CC1)=O)=O)N1C=NN=N1
|
| InChi Key |
WYFCZWSWFGJODV-MIANJLSGSA-N
|
| InChi Code |
InChI=1S/C32H28ClFN8O5/c1-39-15-16-40(28(44)17-39)25-4-2-3-22-21(25)13-14-41(30(22)31(45)36-20-7-5-19(6-8-20)32(46)47)27(43)12-9-23-26(42-18-35-37-38-42)11-10-24(33)29(23)34/h2-12,18,30H,13-17H2,1H3,(H,36,45)(H,46,47)/b12-9+/t30-/m0/s1
|
| Chemical Name |
(S,E)-4-(2-(3-(3-Chloro-2-fluoro-6-(1H-tetrazol-1-yl)phenyl)acryloyl)-5-(4-methyl-2-oxopiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic
acid
|
| Synonyms |
BMS-962212 BMS 962212 BMS962212
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~379.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.16 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5173 mL | 7.5864 mL | 15.1729 mL | |
| 5 mM | 0.3035 mL | 1.5173 mL | 3.0346 mL | |
| 10 mM | 0.1517 mL | 0.7586 mL | 1.5173 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03197779 | COMPLETED | Drug: BMS-962212 Drug: Aspirin Other: Placebo |
Thrombosis | Bristol-Myers Squibb | 2013-11-18 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA